Company MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for MorphoSys AG

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:35:54 2024-04-23 am EDT			After market 03:12:57 pm
67.75 ^EUR	0.00%		67.55	-0.30%

Apr. 11	Health Care Slips on Risk Bias -- Health Care Roundup	DJ
Apr. 11	Trending : Novartis Begins Tender Offer for MorphoSys Shares	DJ

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Number of employees: 524

EUR in Million	2022	Weight	2023	Weight	Delta
Innovative Cancer Medicines 100.0 %	278	100.0 %	238	100.0 %	-14.37%

EUR in Million	2022	Weight	2023	Weight	Delta
United States 88.8 %	0	0.0 %	211	88.8 %	-
Europe (excluding Germany) 11.2 %	-	-	27	11.2 %	-
Asia 0.0 %	-	-	0	0.0 %	-

Managers	Title	Age	Since
Jean-Paul Kress CEO	Chief Executive Officer	59	19-08-31
Lucinda Crabtree DFI	Director of Finance/CFO	45	23-08-06
Luisa Ciccarelli CTO	Chief Tech/Sci/R&D Officer	-	21-07-31
Tim Demuth CTO	Chief Tech/Sci/R&D Officer	50	22-09-30
Julia Neugebauer IRC	Investor Relations Contact	-	06-08-31
Daniel Palmacci PRN	Corporate Officer/Principal	-	20-06-30
Ann Merchant PRN	Corporate Officer/Principal	59	17-12-31
Ralf Ostendorp PRN	Corporate Officer/Principal	-	98-12-31
Günter Wellnhofer PRN	Corporate Officer/Principal	-	94-04-30
Klaus de Wall AUD	Comptroller/Controller/Auditor	-	05-05-31

Members of the board	Title	Age	Since
Michael Brosnan BRD	Director/Board Member	69	18-05-16
George Golumbeski BRD	Director/Board Member	67	18-05-16
Marc Cluzel CHM	Chairman	69	12-05-30
Andrew Cheng BRD	Director/Board Member	57	22-05-17
Krisja Vermeylen BRD	Director/Board Member	62	16-12-31
Sharon Curran BRD	Director/Board Member	56	19-05-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,716,423	31,528,877 ( 83.59 %)	53,685 ( 0.1423 %)	83.59 %

Name	Equities	%	Valuation
NOVARTIS AG 11.57 %	4,360,100	11.57 %	316 M €
Kynam Capital Management LP 11.12 %	4,190,331	11.12 %	304 M €
Goldman Sachs & Co. LLC (Private Banking) 10.99 %	4,141,089	10.99 %	301 M €
Adage Capital Management LP 5.017 %	1,890,000	5.017 %	137 M €
Norges Bank Investment Management 4.181 %	1,575,062	4.181 %	114 M €
RP Management LLC (Investment Management) 3.550 %	1,337,552	3.550 %	97 M €
Caligan Partners LP 2.808 %	1,057,962	2.808 %	77 M €
DWS Investment GmbH 2.616 %	985,701	2.616 %	72 M €
Baillie Gifford & Co. 2.217 %	835,292	2.217 %	61 M €
Credit Suisse Asset Management Ltd. 0.3481 %	131,136	0.3481 %	10 M €

Name	Equities	%	Valuation
T. Rowe Price Investment Management, Inc. 4.268 %	6,431,063	4.268 %	117 M €
Kynam Capital Management LP 2.810 %	4,234,685	2.810 %	77 M €
Point72 Asset Management LP 2.523 %	3,802,846	2.523 %	69 M €
T Rowe Price Associates, Inc. (13F Subfiler) 1.800 %	2,712,552	1.800 %	49 M €
Logos Global Management LP 0.9788 %	1,475,000	0.9788 %	27 M €
Aperio Group LLC 0.5737 %	864,600	0.5737 %	16 M €
TD Asset Management, Inc. (13F Subfiler) 0.2396 %	361,138	0.2396 %	7 M €
Millennium Management LLC 0.2189 %	329,901	0.2189 %	6 M €
Marshall Wace LLP 0.2164 %	326,086	0.2164 %	6 M €
Susquehanna Securities LLC 0.2098 %	316,212	0.2098 %	6 M €

MorphoSys AG

Semmelweisstrasse 7

82152, Planegg

+49 89 899 27-0

http://www.morphosys.de

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

67.75 EUR

Average target price

58.71 EUR

Spread / Average Target

-13.34%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+99.12%	2.72B
IQVIA HOLDINGS INC.	+2.48%	42.11B
LONZA GROUP AG	+48.83%	40.08B
MODERNA, INC.	+7.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.66%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-22.67%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.91%	11.94B
MEDPACE HOLDINGS, INC.	+17.17%	11.66B
UNITED THERAPEUTICS CORPORATION	+7.98%	11.01B

Other Biotechnology & Medical Research